Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?

References

• Lewy FH. Zur pathologischen anatomie der Paralysis Agitans. Dtsch. Z. Nervenheilkd. 50, 50–55 (1913).
   Google Scholar
• Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 388(6645), 839–840 (1997).
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Gai WP, Braak E. Alpha-synuclein is not a requisite component of synaptic boutons in the adult human central nervous system. J. Chem. Neuroanat. 20(3–4), 245–252 (2000).
   PubMedGoogle Scholar
• Yu S, Uéda K, Chan P. Alpha-synuclein and dopamine metabolism. Mol. Neurobiol. 31(1–3), 243–254 (2005).
   PubMed Web of Science ®Google Scholar
• Halliday GM, Ophof A, Broe M et al. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson’s disease. Brain 128(Pt 11), 2654–2664 (2005).
   PubMed Web of Science ®Google Scholar
• Mori F, Tanji K, Yoshimoto M, Takahashi H, Wakabayashi K. Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. Exp. Neurol. 176(1), 98–104 (2002).
   PubMedGoogle Scholar
• Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 24(2), 197–211 (2003).
   PubMed Web of Science ®Google Scholar
• McKeith IG, Galasko D, Kosaka K et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47(5), 1113–1124 (1996).
   PubMed Web of Science ®Google Scholar
• Harding AJ, Halliday GM. Simplified neuropathological diagnosis of dementia with Lewy bodies. Neuropathol. Appl. Neurobiol. 24(3), 195–201 (1998).
   PubMedGoogle Scholar
• Kosaka K, Iseki E. Dementia with Lewy bodies. Curr. Opin. Neurol. 9(4), 271–275 (1996).
   PubMedGoogle Scholar
• Del Tredici K, Rüb U, De Vos RA, Bohl JR, Braak H. Where does Parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol. 61(5), 413–426 (2002).
   PubMed Web of Science ®Google Scholar
• Dickson DW, Braak H, Duda JE et al. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol. 8(12), 1150–1157 (2009).
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J. Pattern of brain destruction in Parkinson’s and Alzheimer’s diseases. J. Neural Transm. 103(4), 455–490 (1996).
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E, Yilmazer D et al. Amygdala pathology in Parkinson’s disease. Acta Neuropathol. 88(6), 493–500 (1994).
   PubMedGoogle Scholar
• Gaspar P, Gray F. Dementia in idiopathic Parkinson’s disease. A neuropathological study of 32 cases. Acta Neuropathol. 64(1), 43–52 (1984).
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Takahashi H, Oyanagi K, Ikuta F. [Incidental occurrence of Lewy bodies in the brains of elderly patients – the relevance to aging and Parkinson’s disease]. No. To Shinkei 45(11), 1033–1038 (1993).
   PubMedGoogle Scholar
• Forno LS. Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism. J. Am. Geriatr. Soc. 17(6), 557–575 (1969).
   PubMed Web of Science ®Google Scholar
• Irizarry MC, Growdon W, Gomez-Isla T et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson’s disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J. Neuropathol. Exp. Neurol. 57(4), 334–337 (1998).
   PubMedGoogle Scholar
• Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree – a new disease? Clin. Neuropathol. 3(5), 185–192 (1984).
   PubMed Web of Science ®Google Scholar
• Kosaka K. Dementia and neuropathology in Lewy body disease. Adv. Neurol. 60, 456–463 (1993).
   PubMedGoogle Scholar
• Rezaie P, Cairns NJ, Chadwick A, Lantos PL. Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease. Neurosci. Lett. 212(2), 111–114 (1996).
   PubMed Web of Science ®Google Scholar
• Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J. Neurol. Sci. 95(2), 119–139 (1990).
   PubMed Web of Science ®Google Scholar
• Mattila PM, Rinne JO, Helenius H, Dickson DW, Röyttä M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease. Acta Neuropathol. 100(3), 285–290 (2000).
   PubMed Web of Science ®Google Scholar
• Churchyard A, Lees AJ. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson’s disease. Neurology 49(6), 1570–1576 (1997).
   PubMedGoogle Scholar
• Hurtig HI, Trojanowski JQ, Galvin J et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 54(10), 1916–1921 (2000).
   PubMed Web of Science ®Google Scholar
• Kuzuhara S, Yoshimura M. Clinical and neuropathological aspects of diffuse Lewy body disease in the elderly. Adv. Neurol. 60, 464–469 (1993).
   PubMedGoogle Scholar
• Kosaka K, Mehraein P. Dementia-Parkinsonism syndrome with numerous Lewy bodies and senile plaques in cerebral cortex. Arch. Psychiatr. Nervenkr. 226(4), 241–250 (1979).
   PubMedGoogle Scholar
• Gai WP, Blessing WW, Blumbergs PC. Ubiquitin-positive degenerating neurites in the brainstem in Parkinson’s disease. Brain 118(Pt 6), 1447–1459 (1995).
   PubMedGoogle Scholar
• Beach TG, Adler CH, Lue L et al.; Arizona Parkinson’s Disease Consortium. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 117(6), 613–634 (2009).
   PubMed Web of Science ®Google Scholar
• Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG; MRC Cognitive Function, Ageing Neuropathology Study. Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 70(13), 1042–1048 (2008).
   PubMed Web of Science ®Google Scholar
• Frigerio R, Fujishiro H, Ahn TB et al. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol. Aging 32(5), 857–863 (2011).
   PubMedGoogle Scholar
• Jellinger KA. Alpha-synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution – a pilot study. Acta Neuropathol. 106(3), 191–201 (2003).
   PubMedGoogle Scholar
• Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J. Neural Transm. 111(10–11), 1219–1235 (2004).
   PubMed Web of Science ®Google Scholar
• Parkkinen L, Soininen H, Alafuzoff I. Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. J. Neuropathol. Exp. Neurol. 62(4), 363–367 (2003).
   PubMedGoogle Scholar
• Parkkinen L, Kauppinen T, Pirttilä T, Autere JM, Alafuzoff I. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann. Neurol. 57(1), 82–91 (2005).
   PubMedGoogle Scholar
• Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol. 115(4), 399–407 (2008).
   PubMed Web of Science ®Google Scholar
• Sonnen JA, Postupna N, Larson EB et al. Pathologic correlates of dementia in individuals with Lewy body disease. Brain Pathol. 20(3), 654–659 (2010).
   PubMed Web of Science ®Google Scholar
• Double KL, Halliday GM, McRitchie DA, Reid WG, Hely MA, Morris JG. Regional brain atrophy in idiopathic Parkinson’s disease and diffuse Lewy body disease. Dementia 7(6), 304–313 (1996).
   PubMedGoogle Scholar
• Dalaker TO, Zivadinov R, Larsen JP et al. Gray matter correlations of cognition in incident Parkinson’s disease. Mov. Disord. 25(5), 629–633 (2010).
   PubMedGoogle Scholar
• Harding AJ, Stimson E, Henderson JM, Halliday GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson’s disease. Brain 125(Pt 11), 2431–2445 (2002).
   PubMed Web of Science ®Google Scholar
• Kingsbury AE, Bandopadhyay R, Silveira-Moriyama L et al. Brain stem pathology in Parkinson’s disease: an evaluation of the Braak staging model. Mov. Disord. 25(15), 2508–2515 (2010).
   PubMedGoogle Scholar
• Hoogendijk WJ, Pool CW, Troost D, van Zwieten E, Swaab DF. Image analyser-assisted morphometry of the locus coeruleus in Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Brain 118(Pt 1), 131–143 (1995).
   PubMedGoogle Scholar
• Pedersen KM, Marner L, Pakkenberg H, Pakkenberg B. No global loss of neocortical neurons in Parkinson’s disease: a quantitative stereological study. Mov. Disord. 20(2), 164–171 (2005).
   PubMedGoogle Scholar
• Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20(4), 415–455 (1973).
   PubMed Web of Science ®Google Scholar
• Greenfield JG, Bosanquet FD. The brain-stem lesions in Parkinsonism. J. Neurol. Neurosurg. Psychiatr. 16(4), 213–226 (1953).
   PubMed Web of Science ®Google Scholar
• Gibb WR. Neuropathology of the substantia nigra. Eur. Neurol. 31(Suppl. 1), 48–59 (1991).
   PubMedGoogle Scholar
• Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114(Pt 5), 2283–2301 (1991).
   PubMedGoogle Scholar
• Halliday GM, McRitchie DA, Cartwright H, Pamphlett R, Hely MA, Morris JG. Midbrain neuropathology in idiopathic Parkinson’s disease and diffuse Lewy body disease. J. Clin. Neurosci. 3(1), 52–60 (1996).
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Mori F, Takahashi H. Progression patterns of neuronal loss and Lewy body pathology in the substantia nigra in Parkinson’s disease. Parkinsonism. Relat. Disord. 12(Suppl. 2), S92–S98 (2006).
   Google Scholar
• MacDonald V, Halliday GM. Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson’s disease. Mov. Disord. 17(6), 1166–1173 (2002).
   PubMed Web of Science ®Google Scholar
• Henderson JM, Carpenter K, Cartwright H, Halliday GM. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson’s disease: clinical and therapeutic implications. Brain 123 (Pt 7), 1410–1421 (2000).
   PubMedGoogle Scholar
• McRitchie DA, Cartwright HR, Halliday GM. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson’s disease. Exp. Neurol. 144(1), 202–213 (1997).
   PubMedGoogle Scholar
• Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav. Brain Res. 221(2), 564–573 (2011).
   PubMed Web of Science ®Google Scholar
• Fronczek R, Overeem S, Lee SY et al. Hypocretin (orexin) loss in Parkinson’s disease. Brain 130(Pt 6), 1577–1585 (2007).
   PubMed Web of Science ®Google Scholar
• Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson’s disease. Brain 130(Pt 6), 1586–1595 (2007).
   PubMed Web of Science ®Google Scholar
• Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson’s disease. Brain Res. 510(1), 104–107 (1990).
   PubMed Web of Science ®Google Scholar
• Greffard S, Verny M, Bonnet AM et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch. Neurol. 63(4), 584–588 (2006).
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson’s disease. Adv. Anat. Embryol. Cell Biol. 201, 1–119 (2009).
   PubMed Web of Science ®Google Scholar
• Paleologou KE, Kragh CL, Mann DM et al. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 132(Pt 4), 1093–1101 (2009).
   PubMed Web of Science ®Google Scholar
• Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4(11), 1318–1320 (1998).
   PubMed Web of Science ®Google Scholar
• Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97(2), 571–576 (2000).
   PubMed Web of Science ®Google Scholar
• Double KL, Dedov VN, Fedorow H et al. The comparative biology of neuromelanin and lipofuscin in the human brain. Cell. Mol. Life Sci. 65(11), 1669–1682 (2008).
   PubMedGoogle Scholar
• Zecca L, Zucca FA, Albertini A, Rizzio E, Fariello RG. A proposed dual role of neuromelanin in the pathogenesis of Parkinson’s disease. Neurology 67(7 Suppl. 2), S8–S11 (2006).
   PubMed Web of Science ®Google Scholar
• Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol. 8(4), 382–397 (2009).
   PubMed Web of Science ®Google Scholar
• Lv Z, Jiang H, Xu H, Song N, Xie J. Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson’s disease. J. Neural Transm. 118(3), 361–369 (2011).
   PubMed Web of Science ®Google Scholar
• Gray DA, Woulfe J. Lipofuscin and aging: a matter of toxic waste. Sci. Aging. Knowledge. Environ. 2005(5), re1 (2005).
   PubMedGoogle Scholar
• Double KL, Reyes S, Werry EL, Halliday GM. Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog. Neurobiol. 92(3), 316–329 (2010).
   PubMedGoogle Scholar
• Saxena S, Caroni P. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron 71(1), 35–48 (2011).
   PubMed Web of Science ®Google Scholar
• Mori F, Tanji K, Zhang H, Kakita A, Takahashi H, Wakabayashi K. Alpha-synuclein pathology in the neostriatum in Parkinson’s disease. Acta Neuropathol. 115(4), 453–459 (2008).
   PubMed Web of Science ®Google Scholar
• Halliday GM, Stevens CH. Glia: initiators and progressors of pathology in Parkinson’s disease. Mov. Disord. 26(1), 6–17 (2011).
   PubMed Web of Science ®Google Scholar
• Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 122(2), 187–204 (2011).
   PubMed Web of Science ®Google Scholar
• Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ. Patterns of levodopa response in Parkinson’s disease: a clinico–pathological study. Brain 130(Pt 8), 2123–2128 (2007).
   PubMedGoogle Scholar
• Halliday GM, Del Tredici K, Braak H. Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson’s disease. J. Neural Transm. Suppl. 70, 99–103 (2006).
   Google Scholar
• Jankovic J. Progression of Parkinson disease: are we making progress in charting the course? Arch. Neurol. 62(3), 351–352 (2005).
   PubMedGoogle Scholar
• De La Fuente-Fernandez R, Schulzer M, Kuramoto L et al. Age-specific progression of nigrostriatal dysfunction in Parkinson’s disease. Ann. Neurol. 69, 803–810 (2011).
   PubMedGoogle Scholar
• van der Flier WM, Scheltens P. Epidemiology and risk factors of dementia. J. Neurol. Neurosurg. Psychiatr. 76(Suppl. 5), v2–v7 (2005).
   PubMed Web of Science ®Google Scholar
• Wakisaka Y, Furuta A, Tanizaki Y, Kiyohara Y, Iida M, Iwaki T. Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study. Acta Neuropathol. 106(4), 374–382 (2003).
   PubMed Web of Science ®Google Scholar
• Kempster PA, O’Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study. Brain 133(Pt 6), 1755–1762 (2010).
   PubMed Web of Science ®Google Scholar
• Reid WG, Hely MA, Morris JG, Loy C, Halliday GM. Dementia in Parkinson’s disease: a 20-year neuropsychological study (Sydney Multicentre Study). J. Neurol. Neurosurg. Psychiatr. 82(9), 1033–1037 (2011).
   PubMed Web of Science ®Google Scholar
• Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. 102(4), 355–363 (2001).
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatr. 55(3), 181–184 (1992).
   PubMed Web of Science ®Google Scholar
• Ballard C, Ziabreva I, Perry R et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67(11), 1931–1934 (2006).
   PubMed Web of Science ®Google Scholar
• Halliday GM, McCann H. The progression of pathology in Parkinson’s disease. Ann. NY Acad. Sci. 1184, 188–195 (2010).
   PubMed Web of Science ®Google Scholar
• Chu Y, Kordower JH. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson’s disease? Neurobiol. Dis. 25(1), 134–149 (2007).
   PubMed Web of Science ®Google Scholar
• Saito Y, Kawashima A, Ruberu NN et al. Accumulation of phosphorylated alpha-synuclein in aging human brain. J. Neuropathol. Exp. Neurol. 62(6), 644–654 (2003).
   PubMedGoogle Scholar
• Saito Y, Ruberu NN, Sawabe M et al. Lewy body-related alpha-synucleinopathy in aging. J. Neuropathol. Exp. Neurol. 63(7), 742–749 (2004).
   PubMedGoogle Scholar
• Aho L, Parkkinen L, Pirttila T, Alafuzoff I. Systematic appraisal using immunohistochemistry of brain pathology in aged and demented subjects. Dement. Geriatr. Cogn. Disord. 25(5), 423–432 (2008).
   PubMedGoogle Scholar
• Mikolaenko I, Pletnikova O, Kawas CH et al. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J. Neuropathol. Exp. Neurol. 64(2), 156–162 (2005).
   PubMed Web of Science ®Google Scholar
• Markesbery WR, Jicha GA, Liu H, Schmitt FA. Lewy body pathology in normal elderly subjects. J. Neuropathol. Exp. Neurol. 68(7), 816–822 (2009).
   PubMedGoogle Scholar
• Adler CH, Connor DJ, Hentz JG et al. Incidental Lewy body disease: clinical comparison to a control cohort. Mov. Disord. 25(5), 642–646 (2010).
   PubMed Web of Science ®Google Scholar
• Bloch A, Probst A, Bissig H, Adams H, Tolnay M. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol. Appl. Neurobiol. 32(3), 284–295 (2006).
   PubMed Web of Science ®Google Scholar
• Parkkinen L, Soininen H, Laakso M, Alafuzoff I. Alpha-synuclein pathology is highly dependent on the case selection. Neuropathol. Appl. Neurobiol. 27(4), 314–325 (2001).
   PubMedGoogle Scholar
• Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72(5), 432–438 (2009).
   PubMed Web of Science ®Google Scholar
• DelleDonne A, Klos KJ, Fujishiro H et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch. Neurol. 65(8), 1074–1080 (2008).
   PubMedGoogle Scholar
• Beach TG, Adler CH, Sue LI et al. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol. 115(4), 445–451 (2008).
   PubMed Web of Science ®Google Scholar
• Londos E, Passant U, Gustafson L, Brun A. Neuropathological correlates to clinically defined dementia with Lewy bodies. Int. J. Geriatr. Psychiatry 16(7), 667–679 (2001).
   PubMedGoogle Scholar
• Marui W, Iseki E, Kato M, Akatsu H, Kosaka K. Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer’s disease. Acta Neuropathol. 108(2), 121–128 (2004).
   PubMed Web of Science ®Google Scholar
• Tatsch K. Imaging of the dopaminergic system in differential diagnosis of dementia. Eur. J. Nucl. Med. Mol. Imaging 35(Suppl. 1), S51–S57 (2008).
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J. Neurofibrillary tangles and neuropil threads as a cause of dementia in Parkinson’s disease. J. Neural Transm. Suppl. 51, 49–55 (1997).
   PubMedGoogle Scholar
• Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease: a critical analysis of alpha-synuclein staging. Neuropathol. Appl. Neurobiol. 34(3), 284–295 (2008).
   PubMedGoogle Scholar
• Attems J, Jellinger KA. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease. Neuropathol. Appl. Neurobiol. 34(4), 466–467 (2008).
   PubMedGoogle Scholar
• Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson’s disease. Ann. Neurol. 64(5), 485–491 (2008).
   PubMed Web of Science ®Google Scholar
• Greffard S, Verny M, Bonnet AM, Seilhean D, Hauw JJ, Duyckaerts C. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiol. Aging 31(1), 99–103 (2010).
   PubMed Web of Science ®Google Scholar
• Braak H, Rüb U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64(8), 1404–1410 (2005).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. J. Neural Transm. Suppl. 72, 91–104 (2007).
   Google Scholar
• Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA. In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology 69(4), 356–359 (2007).
   PubMedGoogle Scholar
• Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol. 115(4), 409–415 (2008).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim. Biophys. Acta 1792(7), 730–740 (2009).
   PubMedGoogle Scholar
• Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson’s disease. Brain Pathol. 20(3), 633–639 (2010).
   PubMedGoogle Scholar
• Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch. Neurol. 59(1), 102–112 (2002).
   PubMed Web of Science ®Google Scholar
• Braak H, Rüb U, Del Tredici K. Cognitive decline correlates with neuropathological stage in Parkinson’s disease. J. Neurol. Sci. 248(1–2), 255–258 (2006).
   PubMed Web of Science ®Google Scholar
• Colosimo C, Hughes AJ, Kilford L, Lees AJ. Lewy body cortical involvement may not always predict dementia in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 74(7), 852–856 (2003).
   PubMedGoogle Scholar
• Wolters ECh, Braak H. Parkinson’s disease: premotor clinico-pathological correlations. J. Neural Transm. Suppl. 70, 309–319 (2006).
   Google Scholar
• Stephenson R, Siderowf A, Stern MB. Premotor Parkinson’s disease: clinical features and detection strategies. Mov. Disord. 24(Suppl. 2), S665–S670 (2009).
   PubMedGoogle Scholar
• Tolosa E, Gaig C, Santamaría J, Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology 72(Suppl. 7), S12–S20 (2009).
   PubMed Web of Science ®Google Scholar
• Lang AE. A critical appraisal of the premotor symptoms of Parkinson’s disease: potential usefulness in early diagnosis and design of neuroprotective trials. Mov. Disord. 26(5), 775–783 (2011).
   PubMed Web of Science ®Google Scholar
• Tolosa E, Pont-Sunyer C. Progress in defining the premotor phase of Parkinson’s disease. J. Neurol. Sci. 310(1–2), 4–8 (2011).
   PubMedGoogle Scholar
• Postuma RB, Gagnon JF, Montplaisir JY. REM sleep behavior disorder: from dreams to neurodegeneration. Neurobiol. Dis. 46(3), 553–558 (2012).
   PubMedGoogle Scholar
• Ju YE, Larson-Prior L, Duntley S. Changing demographics in REM sleep behavior disorder: possible effect of autoimmunity and antidepressants. Sleep Med. 12(3), 278–283 (2011).
   PubMed Web of Science ®Google Scholar
• Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 72(15), 1296–1300 (2009).
   PubMed Web of Science ®Google Scholar
• Iranzo A, Valldeoriola F, Lomeña F et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 10(9), 797–805 (2011).
   PubMed Web of Science ®Google Scholar
• Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 75(6), 494–499 (2010).
   PubMed Web of Science ®Google Scholar
• Naismith SL, Terpening Z, Shine JM, Lewis SJ. Neuropsychological functioning in Parkinson’s disease: differential relationships with self-reported sleep-wake disturbances. Mov. Disord. 26(8), 1537–1541 (2011).
   PubMed Web of Science ®Google Scholar
• Gagnon JF, Vendette M, Postuma RB et al. Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson’s disease. Ann. Neurol. 66(1), 39–47 (2009).
   PubMed Web of Science ®Google Scholar
• Marion MH, Qurashi M, Marshall G, Foster O. Is REM sleep behaviour disorder (RBD) a risk factor of dementia in idiopathic Parkinson’s disease? J. Neurol. 255(2), 192–196 (2008).
   PubMed Web of Science ®Google Scholar
• Vendette M, Gagnon JF, Décary A et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology 69(19), 1843–1849 (2007).
   PubMed Web of Science ®Google Scholar
• Sinforiani E, Pacchetti C, Zangaglia R, Pasotti C, Manni R, Nappi G. REM behavior disorder, hallucinations and cognitive impairment in Parkinson’s disease: a two-year follow up. Mov. Disord. 23(10), 1441–1445 (2008).
   PubMedGoogle Scholar
• Terzaghi M, Sinforiani E, Zucchella C et al. Cognitive performance in REM sleep behaviour disorder: a possible early marker of neurodegenerative disease? Sleep Med. 9(4), 343–351 (2008).
   PubMed Web of Science ®Google Scholar
• Sinforiani E, Zangaglia R, Manni R et al. REM sleep behavior disorder, hallucinations, and cognitive impairment in Parkinson’s disease. Mov. Disord. 21(4), 462–466 (2006).
   PubMed Web of Science ®Google Scholar
• Boeve BF, Silber MH, Saper CB et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 130(Pt 11), 2770–2788 (2007).
   PubMed Web of Science ®Google Scholar
• Nelson PT, Jicha GA, Kryscio RJ et al. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J. Neurol. 257(3), 359–366 (2010).
   PubMedGoogle Scholar
• Nelson PT, Kryscio RJ, Jicha GA et al. Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies. Neurology 73(14), 1127–1133 (2009).
   PubMed Web of Science ®Google Scholar
• Weiner MW, Aisen PS, Jack CR Jr et al.; Alzheimer’s Disease Neuroimaging Initiative. The Alzheimer’s disease neuroimaging initiative: progress report and future plans. Alzheimers. Dement. 6(3), 202–11.e7 (2010).
   PubMed Web of Science ®Google Scholar
• Fodero-Tavoletti MT, Okamura N, Furumoto S et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease. Brain 134(Pt 4), 1089–1100 (2011).
   PubMed Web of Science ®Google Scholar
• Gerhard A, Pavese N, Hotton G et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol. Dis. 21, 404–412 (2006).
   PubMed Web of Science ®Google Scholar
• Ouchi Y, Yoshikawa E, Sekine Y et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann. Neurol. 57(2), 168–175 (2005).
   PubMed Web of Science ®Google Scholar
• Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA, Leenders KL. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson’s disease? Parkinsonism Relat. Disord. 16(1), 57–59 (2010).
   PubMedGoogle Scholar
• Angot E, Steiner JA, Hansen C, Li JY, Brundin P. Are synucleinopathies prion-like disorders? Lancet Neurol. 9(11), 1128–1138 (2010).
   PubMed Web of Science ®Google Scholar
• Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell Biol. 11(4), 301–307 (2010).
   PubMed Web of Science ®Google Scholar
• Guest WC, Silverman JM, Pokrishevsky E, O’Neill MA, Grad LI, Cashman NR. Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit. J. Toxicol. Environ. Health Part A 74(22–24), 1433–1459 (2011).
   PubMed Web of Science ®Google Scholar
• Hilker R, Brotchie JM, Chapman J. Pros and cons of a prion-like pathogenesis in Parkinson’s disease. BMC Neurol. 11, 74 (2011).
   PubMedGoogle Scholar
• Lee SJ, Desplats P, Sigurdson C, Tsigelny I, Masliah E. Cell-to-cell transmission of non-prion protein aggregates. Nat. Rev. Neurol. 6(12), 702–706 (2010).
   PubMed Web of Science ®Google Scholar
• Brundin P, Li JY, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson’s disease pathology spread. Nat. Rev. Neurosci. 9(10), 741–745 (2008).
   PubMed Web of Science ®Google Scholar
• Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 110(5), 517–536 (2003).
   PubMed Web of Science ®Google Scholar
• Lee SJ, Lim HS, Masliah E, Lee HJ. Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci. Res. 70(4), 339–348 (2011).
   PubMed Web of Science ®Google Scholar
• McKeith IG, Dickson DW, Lowe J et al.; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12), 1863–1872 (2005).
   PubMed Web of Science ®Google Scholar
• Armstrong RA, Cairns NJ, Lantos PL. Dementia with Lewy bodies: clustering of Lewy bodies in human patients. Neurosci. Lett. 224(1), 41–44 (1997).
   PubMedGoogle Scholar
• Weintraub D, Comella CL, Horn S. Parkinson’s disease – Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. Am. J. Manag. Care 14(Suppl. 2), S40–S48 (2008).
   PubMed Web of Science ®Google Scholar
• Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet 373(9680), 2055–2066 (2009).
   PubMed Web of Science ®Google Scholar
• Williams MM, Xiong C, Morris JC, Galvin JE. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology 67(11), 1935–1941 (2006).
   PubMed Web of Science ®Google Scholar
• Müller CM, de Vos RA, Maurage CA, Thal DR, Tolnay M, Braak H. Staging of sporadic Parkinson disease-related alpha-synuclein pathology: inter- and intra-rater reliability. J. Neuropathol. Exp. Neurol. 64(7), 623–628 (2005).
   PubMed Web of Science ®Google Scholar
• Dickson DW, Fujishiro H, DelleDonne A et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease. Acta Neuropathol. 115(4), 437–444 (2008).
   PubMed Web of Science ®Google Scholar
• Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. Controversies over the staging of alpha-synuclein pathology in Parkinson’s disease. Acta Neuropathol. 116(1), 125–128; author reply 129 (2008).
   PubMed Web of Science ®Google Scholar
• Dickson DW, Uchikado H, Fujishiro H, Tsuboi Y. Evidence in favor of Braak staging of Parkinson’s disease. Mov. Disord. 25(Suppl. 1), S78–S82 (2010).
   Google Scholar